Brokerages Set Immatics N.V. (NASDAQ:IMTX) Price Target at $14.67

Key Points

• Immatics N.V. has received a consensus rating of Moderate Buy from analysts, with one sell rating, four buy ratings, and one strong buy rating.
• The company's average twelve-month target price is $14.67, although the stock currently trades significantly lower at around $5.72.
• Immatics recently reported earnings of ($0.66) per share, missing estimates, with quarterly revenue of $6.48 million compared to expectations of $13.05 million.

Shares of Immatics N.V. (NASDAQ:IMTX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the six research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $14.6667.

Several research analysts have recently commented on the stock. Wall Street Zen lowered shares of Immatics from a "hold" rating to a "strong sell" rating in a report on Thursday, May 22nd. Deutsche Bank Aktiengesellschaft started coverage on shares of Immatics in a report on Wednesday, May 28th. They issued a "buy" rating and a $10.00 price target for the company. Finally, Zacks Research lowered shares of Immatics from a "hold" rating to a "strong sell" rating in a research note on Friday, August 15th.

Hedge Funds Weigh In On Immatics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IMTX. Bank of America Corp DE grew its holdings in Immatics by 166.0% in the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company's stock worth $25,000 after buying an additional 2,231 shares in the last quarter. Vontobel Holding Ltd. bought a new position in Immatics in the 2nd quarter worth approximately $59,000. Intellectus Partners LLC bought a new position in Immatics in the 1st quarter worth approximately $70,000. Forefront Analytics LLC grew its holdings in Immatics by 42.3% in the 4th quarter. Forefront Analytics LLC now owns 15,911 shares of the company's stock worth $113,000 after buying an additional 4,731 shares in the last quarter. Finally, Exchange Traded Concepts LLC grew its holdings in Immatics by 94.5% in the 1st quarter. Exchange Traded Concepts LLC now owns 25,580 shares of the company's stock worth $115,000 after buying an additional 12,425 shares in the last quarter. 64.41% of the stock is owned by institutional investors.

Immatics Stock Performance

Shares of NASDAQ IMTX traded up $0.15 during midday trading on Friday, hitting $5.94. The company's stock had a trading volume of 115,624 shares, compared to its average volume of 778,514. Immatics has a 1-year low of $3.30 and a 1-year high of $13.09. The firm's fifty day moving average price is $5.96 and its 200-day moving average price is $5.25. The firm has a market cap of $722.01 million, a P/E ratio of -9.13 and a beta of 1.02.

Immatics (NASDAQ:IMTX - Get Free Report) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.28). Immatics had a negative net margin of 59.29% and a negative return on equity of 15.60%. The business had revenue of $6.48 million during the quarter, compared to analyst estimates of $13.05 million. As a group, research analysts predict that Immatics will post -0.72 earnings per share for the current fiscal year.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.